RAFF4 Trial: Vernakalant vs. Procainamide for Acute Atrial Fibrillation in the Emergency Department

PHASE4CompletedINTERVENTIONAL
Enrollment

350

Participants

Timeline

Start Date

June 17, 2021

Primary Completion Date

September 15, 2024

Study Completion Date

November 6, 2024

Conditions
Atrial Fibrillation
Interventions
DRUG

Vernakalant

an initial infusion of 3 mg/kg infused over a 10-minute period by a pre-programmed IV pump

DRUG

Procainamide

15 mg/kg in 500 mL of normal saline given over 60 minutes

Trial Locations (14)

T6G 2B7

University of Alberta Hospital, Edmonton

V5Z 1M9

Vancouver General Hospital, Vancouver

Unknown

St. Paul's Hospital, Vancouver

Queen Elizabeth II Health Sciences Centre, Halifax

St. Michaels, Toronto

Sunnybrook Hospital, Toronto

Institut universitaire de cardiologie et de pneumologie de Québec-Université Laval, Laval

Hopital Du Sacre-Coeur, Montreal

Hopital de L'Enfant-Jesus, Québec

Hôtel-Dieu de Lévis, Québec

l8L 2X2

Hamilton Health Sciences Centre, Hamilton

K2L 2V7

Kingston Health Sciences Centre, Kingston

K1Y 4E9

Ottawa Hospital, Ottawa

H1T 1C8

Montreal Heart Institute, Montreal

All Listed Sponsors
lead

Ottawa Hospital Research Institute

OTHER